AZD4547 + paclitaxel
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastro-oesophageal Junction Cancer
Conditions
Gastro-oesophageal Junction Cancer, Gastric Cancer
Trial Timeline
Nov 1, 2011 → Feb 1, 2015
NCT ID
NCT01457846About AZD4547 + paclitaxel
AZD4547 + paclitaxel is a phase 2 stage product being developed by AstraZeneca for Gastro-oesophageal Junction Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01457846. Target conditions include Gastro-oesophageal Junction Cancer, Gastric Cancer.
What happened to similar drugs?
1 of 2 similar drugs in Gastro-oesophageal Junction Cancer were approved
Approved (1) Terminated (0) Active (1)
🔄Regorafenib + Nivolumab + Docetaxel + Paclitaxel + Irinotecan + Trifluridine/TipracilBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01457846 | Phase 2 | Terminated |
Competing Products
4 competing products in Gastro-oesophageal Junction Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD8931 + Placebo + Paclitaxel | AstraZeneca | Phase 2 | 27 |
| Esomeprazole | AstraZeneca | Approved | 43 |
| Bemarituzumab + Flot regimen | Amgen | Phase 2 | 27 |
| Regorafenib + Nivolumab + Docetaxel + Paclitaxel + Irinotecan + Trifluridine/Tipracil | Bristol Myers Squibb | Phase 3 | 44 |